38491-47-3

Upstream product

• 32363-92-1 1,1-dibromo-3-methyl-1-butene 
• 541-41-3 chloroformic acid ethyl ester 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 95648-08-1 ethyl 4-methyl-3-oxo-2-(triphenylphosphoranylidene)pentanoate 
• 38491-54-2 ethyl 2-diazo-3-hydroxy-4-methylpentanoate 
• 598-23-2 3-methyl-but-1-yne 

Downstream Products

• 959800-65-8 3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazole-4-carboxylic acid ethyl ester 
• 959801-00-4 4-{4-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-2-methyl-benzylamino}-benzoic acid methyl ester 
• 959801-13-9 4-{4-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-2-methyl-phenylethynyl}-benzoic acid methyl ester 
• 959800-98-7 3-(1-{4-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-2-methyl-phenyl}-ethylsulfanyl)-benzoic acid methyl ester 
• 959801-07-1 3-(2-{2-chloro-4-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-phenyl}-vinyl)-benzoic acid methyl ester 
• 959800-97-6 3-(2-(4-(3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy)-2-methyl-phenyl)-vinyl)-benzoic acid methyl ester 
• 959800-96-5 4'-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-2'-methyl-biphenyl-4-carboxylic acid methyl ester 
• 959800-83-0 2-{4-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-2-methyl-phenyl}-propan-2-ol 
• 959800-82-9 1-{4-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-2-methyl-phenyl}-ethanol 
• 959800-79-4 1-{4-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-2-methyl-phenyl}-ethanone 
• 959801-05-9 2-chloro-4-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-benzaldehyde 
• 959800-77-2 5-(4-bromo-3-methyl-phenoxymethyl)-1-(2,6-dichloro-phenyl)-4-isopropyl-1H-[1,2,3]triazole 
• 959800-76-1 methanesulfonic acid 3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethyl ester 
• 959800-67-0 [3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-yl]-methanol 

Relevant academic research and scientific papers

Modulating N- versus O-arylation in pyrazolone-aryl halide couplings

The regioselective, copper-catalyzed coupling of a tautomeric pyrazolone/pyrazole with 2-halopyridines was investigated. Conditions were developed to preferentially form either the N-aryl or O-aryl product.

COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASIS

The present invention relates to compounds of formula (1a), (1b), (1c), (1d) or (1e) and pharmaceutically acceptable salts or solvates thereof for use in the treatment or prevention of fascioliasis. Some of these compounds are novel per se and also have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such novel compounds, salts or solvates and to the use of such novel compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.

HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegen

COMPOUNDS AND THEIR USE IN THE TREATMENT OF SCHISTOSOMIASIS

The present invention relates to novel compounds and pharmaceutically acceptable salts or solvates thereof which have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such compounds, salts or solvates and to the use of such compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.

Development of Gold-catalyzed [4+1] and [2+2+1]/[4+2] Annulations between Propiolate Derivatives and Isoxazoles

Two new gold-catalyzed annulations of isoxazoles with propiolates have been developed. Most isoxazoles follow an initial O attack on the alkyne to afford a [4+1] annulation product. This process results in a remarkable alkyne cleavage of initial propiolates. Unsubstituted isoxazoles proceed through an N attack step to yield formal [2+2+1]/[4+2] annulation products. These two annulation products arise initially from two seven-membered heterocyclic intermediates, which then lead to products.

Gold-catalyzed formal [4π+2π]-cycloadditions of tert-butyl propiolates with aldehydes and ketones to form 4H-1,3-dioxine derivatives

Gold-catalyzed formal hetero-[4π+2π] cycloadditions of tert-butyl propiolates with carbonyl compounds proceeded efficiently to yield 4H-1,3-dioxine derivatives over a wide scope of substrates. With acetone as a promoter, gold-catalyzed cycloadditions of these propiolate derivatives with enol ethers led to the formation of atypical [4+2]-cycloadducts with skeletal rearrangement.

Copper-catalyzed domino route to natural nostoclides and analogues: A total synthesis of nostoclides i and II

An original and convenient domino route to natural nostoclides I and II has been developed using a two-step sequence consisting of a copper-cat-alyzed tandem reaction associated with Suzuki cross-coupling. The methodology employed for this total synthesis appeared to be an interesting and suffi-ciently flexible tool to allow the synthesis of numer-ous analogues of these nostoclides.

Selective one-pot synthesis of allenyl and alkynyl esters from β-ketoesters

(Chemical Equation Presented) A convenient method is described for the dehydration of β-ketoesters to generate conjugated and deconjugated alkynyl esters and conjugated allenyl esters. This sequential one-pot method involves the formation of a vinyl trifl

SELECTIVE ESTROGEN RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE

The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs

COMPOUNDS AND METHODS FOR MODULATING FXR

Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.